Clinical and molecular complexity of breast cancer metastases  by Kimbung, Siker et al.
RC
S
a
b
c
a
A
R
R
A
A
K
B
T
M
O
P
T
1
t
n
h
m
l
r
c
p
s
r
e
d
m
m
c
o
T
h
1
0Seminars in Cancer Biology 35 (2015) 85–95
Contents lists available at ScienceDirect
Seminars  in  Cancer  Biology
j o ur na l ho me  page: www.elsev ier .com/ locate /semcancer
eview
linical  and  molecular  complexity  of  breast  cancer  metastases
iker  Kimbunga,b,  Niklas  Lomana,c, Ingrid  Hedenfalka,b,∗
Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden
CREATE Health Strategic Center for Translational Cancer Research, Lund University, Lund, Sweden
Department of Oncology, Skåne University Hospital, Lund/Malmö, Sweden
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 16 June 2015
eceived in revised form 17 August 2015
ccepted 21 August 2015
vailable online 28 August 2015
eywords:
reast cancer
umor heterogeneity
etastasis
a  b  s  t  r  a  c  t
Clinical  oncology  is  advancing  toward  a  more  personalized  treatment  orientation,  making  the  need  to
understand  the  biology  of  metastasis  increasingly  acute.  Dissecting  the  complex  molecular,  genetic  and
clinical phenotypes  underlying  the  processes  involved  in  the development  of  metastatic  disease,  which
remains  the  principal  cause  of cancer-related  deaths,  could  lead  to  the  identiﬁcation  of  more  effective
prognostication  and  targeted  approaches  to  prevent  and  treat  metastases.  The  past  decade  has  witnessed
signiﬁcant  progress  in the  ﬁeld  of  cancer  metastasis  research.  Clinical  and  technological  milestones  have
been  reached  which  have  tremendously  enriched  our understanding  of  the  complex  pathways  under-
taken  by  primary  tumors  to progress  into  lethal  metastases  and  how  some  of these  processes  might  be
amenable  to therapy.  The  aim  of  this  review  article  is  to highlight  the  recent  advances  toward  unravelingrgan-speciﬁc tropism
rognosis
argeted therapy
the  clinical  and  molecular  complexity  of  breast  cancer  metastases.  We  focus  on  genes  mediating  breast
cancer  metastases  and organ-speciﬁc  tropism,  and  discuss  gene  signatures  for  prediction  of  metastatic
disease.  The  challenges  of translating  this  information  into  clinically  applicable  tools  for  improving
the  prognostication  of  the  metastatic  potential  of  a primary  breast  tumor,  as  well  as for  therapeutic
interventions  against  latent  and  active  metastatic  disease  are  addressed.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Tumor metastasis is a major clinical challenge accounting for
he vast majority of cancer related deaths. Although only 5–10% of
ewly diagnosed breast cancer patients present with cancer that
as metastasized to distant body parts [1–3], the risk of developing
etastatic disease in patients with localized primary disease fol-
owing successful primary tumor resection and adjuvant therapy
emains high. It is estimated that up to 30% of node-negative breast
ancer patients and an even larger fraction of patients with node-
ositive disease will develop metastatic disease despite receiving
tandard treatment [1,4]. These ﬁgures and the fact that distant
ecurrent disease must generally be viewed as an incurable disease
Abbreviations: BBB, blood–brain barrier; BRCA, breast cancer associated; ER,
strogen receptor; CTC, circulating tumor cell; ctDNA, circulating tumor DNA; DRFI,
istant recurrence-free interval; DTC, disseminated tumor cell; EMT, epithelial-to-
esenchymal transition; HER2, human epidermal growth factor receptor 2; MBC,
etastatic breast cancer; PR, progesterone receptor; TNBC, triple-negative breast
ancer.
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/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
indicate the high clinical burden of metastatic breast cancer (MBC)
and underscore the urgent demand for better strategies for clinical
intervention for those more than half a million women world-wide
still succumbing to this disease annually [5].
It has been recognized for some time that breast cancer dis-
semination is a non-random, organotropic process, originally based
on Paget’s theory of “seed and soil” [6]. Factors inﬂuencing the
development and localization of breast cancer metastases have
been identiﬁed and will be discussed in this review. Furthermore,
important associations between molecular subtypes and risk as
well as site/s of recurrence have emerged and will be reviewed
herein. Challenges in the path to clinical translation and how recent
advances in the understanding of the complexity of breast cancer
metastases may  inform future management of early stage breast
cancer patients are addressed.
2. Tumor progression
Tumor progression from an early pre-neoplastic lesion through
invasive cancer to the development of clinically detectable distant
metastases may  be conceived as an evolutionary process, involv-
ing multiple genetic and epigenetic alterations affecting both tumor
cells and the surrounding stroma, allowing seeding of metastases
at distant sites. Although the path toward metastatic colonization
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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s a complex and multi-faceted process, it is also thought to be
ighly inefﬁcient. The likelihood of a circulating tumor cell forming
 metastatic colony in a distant organ is in fact extremely low. Most
ells that leave a tumor die, often due to inability to inﬁltrate distant
rgans [7,8]. Data from preclinical animal studies have shown that
ess than 0.02% of circulating tumor cells can survive and have the
apability to seed metastases [9]. To develop metastases, primary
umor cells must invade and escape from the complex physical bar-
iers (extracellular matrix, basement membrane and vasculature)
t the primary site, intravasate into the lymphatic or vascular sys-
em, exit it to inﬁltrate distant organs and continue to proliferate
n this foreign milieu [10]. In this context, there exists considerable
eterogeneity in the metastatic potential of individual cells within
he bulk of a primary tumor [11–15].
The metastatic propensity of a tumor cell is thought to be inﬂu-
nced by both the cell of origin and the oncogenic alterations
resent in the tumor. For example, the same oncogenic mutations
ccurring in cells at different stages of differentiation or lineages
e.g. stem cells) may  hence lead to distinct metastatic propensities
10,16,17]. In addition, the type of oncogenic driver mutation may
lso inﬂuence the ability of a tumor to metastasize [17].
.1. Linear progression model
The question of when and how metastases spread is com-
lex and has multiple answers. Tumor cells can adopt different
volutionary paths to seed metastases and these paths may  vary
ithin and between different tumors. Two classical models of
umor metastasis are widely acknowledged. Traditionally, it has
een considered that metastatic dissemination is a “late” event,
ccurring when the primary tumor is large [9]. In this linear
rogression model, heterogeneous clones in the primary tumor
ndergo a sequential clonal selection process, during which sub-
lones with metastatic propensity are selected for and undergo
urther mutational changes endowing them with survival advan-
ages and the capacity to grow as overt metastases in different
rgans [14,16,18]. Indeed, primary tumor size is a risk factor for
etastatic progression, providing indirect support for this model
19]. Moreover, early studies reporting similar gene expression
ignatures between metastases and their corresponding primary
umors can be interpreted as further support [20]. This concept
onstitutes the theoretical basis for early detection, e.g. mam-
ography screening, as a tool to reduce metastatic disease. In
ontrast, as reported in other studies [21,22], primary tumors may
lready contain a gene expression proﬁle that is strongly predic-
ive of metastasis and poor survival, thus challenging the notion
hat metastatic ability is acquired late during tumor progression.
iven the wide degree of intra-tumor heterogeneity, analyzing a
ingle small biopsy from a tumor may  underestimate the complex-
ty of the molecular landscape. This factor is a limitation of most
enetic studies performed so far and presents a major challenge to
he interpretation of these correlations as well as to the successful
evelopment of precision medicine [23].
.2. Parallel progression model
The parallel progression model postulates that the metastatic
otential is acquired very early in disease progression, when the
rimary lesion is small or even undetectable. It is based on the
otion that disseminated cells evolve independently of the pri-
ary tumor and that different tumor clones can be seeded in
arallel to distant sites [24,25]. This model implies that cancer
s a systemic disease, requiring systemic (adjuvant) treatment at
n early stage for efﬁcient eradication [25,26]. In support of this
odel are observations demonstrating signiﬁcant genetic differ-
nces between paired primary breast cancers and lymph nodecer Biology 35 (2015) 85–95
metastases [27–29], as well as discordances between primary
tumors and distant relapses when conventional prognostic mark-
ers (ER, PR or HER2) are assessed [30,31]. In the study by Falck et al.
[30], no signiﬁcant discordance in single biomarkers was observed
between primary tumors and synchronous lymph node metas-
tases. However, by combining individual biomarkers to classify
tumors into molecular subtypes according to the St Gallen guide-
lines [32], signiﬁcant discordances in molecular subtypes were
revealed between the primary tumors and lymph node metas-
tases, and the prognosis was  strongly correlated with the subtype
of the metastatic lymph node. Moreover, an inferior outcome has
also been reported when the phenotype differed between pri-
mary and metastatic disease [33–37], suggesting that fundamental
alterations in the course of dissemination occur, thereby affecting
outcome.
The detection and prognostic relevance of circulating tumor
cells (CTCs) in patients with metastatic breast cancer as well as in
patients with early-stage disease [38,39] lends additional evidence
that parallel progression may  occur. Nevertheless, most metastases
are generally detected years, or even decades following diagnosis
and treatment of the primary tumor. From this perspective, CTCs,
disseminated tumor cells (DTCs) in the bone marrow or even cir-
culating cell free tumor DNA (ctDNA) may  be more relevant for
the purposes of predicting disease progression and monitoring
response to treatment [40]. As such, several clinical studies have
been initiated to develop and validate their potential to serve as
powerful tools for non-invasive detection of early/late metastatic
disease and biomarkers for response to therapy.
Irrespective of the route of progression favored by a speciﬁc
tumor, it is still unclear if each metastasis originates from a single
progenitor cell (monoclonal seeding) [14,18], or if polyclonal seed-
ing, where some metastases may  originate from multiple events
involving a heterogeneous mix  of distinct sub-clones from the pri-
mary tumor as well as clones from other metastases [41–43] is an
alternate path. Gundem et al. recently performed whole genome
sequencing of serial primary tumors and metastases from patients
with metastatic prostate cancer and conﬁrmed that metastases
from different organ sites in the same patient had sub-clonal alter-
ations originating from multiple distinct clones, some of which
were also found in the primary tumor, suggesting that this poly-
clonal seeding must have arisen both from the primary tumor
and from other metastases [41–43]. Regardless of the mode of
progression or the origin of metastatic cancer cells, considerable
advancements in the knowledge of the molecular events under-
lying the development of metastatic disease are required before
successful treatment and prevention become a reality.
3. Genes mediating breast cancer metastasis
While many of the transforming genetic and epigenetic changes
necessary for oncogenesis are also necessary for metastatic
progression, the principal steps of the metastatic cascade are
accomplished by four main categories of genes (reviewed in detail
elsewhere [16,17,44]). Brieﬂy, the ﬁrst group, metastasis initia-
tion genes, allow aggressive cells to invade the surrounding tissue,
attract a supportive stroma, facilitate the dispersion of cancer cells
and may  also play a role in inﬁltrating distant metastatic niches.
Several genes involved in epithelial-to-mesenchymal transition
(EMT; e.g. TWIST1, SNAI1,  SNAI2)  [10,16,17,44,45], extracellular
matrix degradation (matrix metalloproteinases, MMPs), hypoxia
(e.g. HIF1A),  and angiogenesis (VEGF) have been associated with this
step. The expression of these metastasis initiation genes and their
target genes in primary tumors is prognostic of poor outcome [16].
Metastasis progression genes comprise the second cate-
gory and co-operate to provide tumor cells with specialized
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Fig. 1. Disease-speciﬁc survival from the time of diagnosis of metastatic disease for patients with hormone receptor positive (HR+) and negative (HR−) disease, respectively,
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igure from [60] reprinted with permission from Oxford University Press.
unctions required for extravasation, survival and reinitiating of
umor growth in the invaded parenchyma in a tissue-speciﬁc man-
er [16]. These genes may  already be prominently expressed in a
rimary tumor, priming tumor cells for the colonization of speciﬁc
istant target organs. Their expression may  hence serve as site-
peciﬁc prognostic markers. Evidence that metastasis progression
enes are already expressed in primary tumors is provided by the
epeated identiﬁcation of gene expression signatures in primary
umors able to predict relapse potential [10,45–47]. The invasive
ront of the primary tumor is a milieu rich in tumor-associated
acrophages, myeloid progenitor cells, newly generated blood
essels and cancer-associated ﬁbroblast [48]. This stroma-rich
nvironment is also a source of developmental and self-renewal
ignals including the NOTCH, and WNT  signaling pathways and
ytokines such as TGF and TNF which support the ﬁtness and
urvival of cancer stem cells. In addition, these factors may  select
or metastatic traits that are necessary for both local and distant
etastatic niches [49]. Examples of metastasis progression genes
nclude PTGS2,  EREG, LOX, ANGPLTL4 and CLDN2 [46,47,50,51].
The third group, metastasis virulence genes, endows dissemi-
ated cells with the competence to overtly colonize distant sites.
requently, there is a latency period (metastatic dormancy period)
etween dissemination and colonization, during which tumor cells
ust attain the necessary alterations to proliferate and survive in
he foreign tissue [16]. This requires the activation of metastasis
irulence genes, implying that their expression is only detectable
n cells within the metastasis, does not provide any advantage to
ancer cells at the primary tumor site, and are generally not present
ithin the gene expression signatures predictive of the metastatic
otential of primary tumors. For example, in order to establish
steolytic metastases, interleukin 11 (IL-11), vascular cell adhesion
olecule 1 (VCAM-1), and parathyroid hormone-related protein
PTHrP) are essential osteoclast mobilizing factors [50,52].
Finally, there exists a group of genes called metastasis suppressor
enes, whose functions contribute to prolonging metastatic latency
nd preventing metastatic cells from reinitiating growth upon inﬁl-
ration of distant organs. Examples of genes in this category include
ystatin E/M (CST6), which has been shown to suppress breast
ancer bone metastases [53], retinoic acid receptor responder
tazarotene induced) 3 (RARRES3),  which was recently identiﬁedas a potential breast cancer lung metastasis suppressor gene [54],
and KiSS-1 metastasis-suppressor (KISS1),  which has metastatic
suppressor functions in breast cancer and other malignancies [55].
4. Organ-speciﬁc tropism of breast cancer metastases
Paget’s “seed and soil” hypothesis for non-random metastatic
spread has since its conception received support from numerous
experimental and clinical studies [12,56,57]. Although the initial
steps of the metastatic cascade may  signiﬁcantly overlap, as men-
tioned previously, colonization of different organs likely requires
distinct traits. The circulation patterns, extravasation barriers, and
potential to survive in foreign tissue constitute three key obstacles
in the path of primary tumor cell colonization of distant organs. Fur-
thermore, other capabilities are required to overcome dormancy
and reinitiate growth to develop into macrometastases [10]. The
unique barriers at various organ sites may  affect the duration
of the latency period. Estrogen receptor (ER) positive (luminal-
like) tumors display protracted metastasis latency periods and
frequently colonize the bone, whereas ER negative tumors display
a shorter course to metastasis development and frequently metas-
tasize to visceral organs [58–61]. This suggests that cells from ER
negative primary tumors may  acquire the critical metastatic traits
earlier during disease progression, excluding the need for extensive
adaptation after dissemination to distant sites [10].
An important factor for determining prognosis following breast
cancer recurrence is tumor burden, which considers the number
of metastatic lesions and the speciﬁc anatomical location of the
metastases. Patients presenting with solitary (oligo) lesions survive
longer than patients with multiple lesions [60]. The distant organs
to which breast cancers metastasize also has clinical implications,
and the site/s involved are known to affect both post-recurrence
survival and overall survival [60,62–64] (Fig. 1). Overall, the most
frequent sites of secondary relapse of breast cancer include the
bone, lungs, liver and brain [61,65], even though a tendency toward
widespread metastases to other sites has been demonstrated [57].
The preferred site of metastatic relapse has also been shown to
differ between the intrinsic subtypes of breast cancer [58,59,61]
(Fig. 2). The skeleton is the most common site of distant metas-
tases, representing the ﬁrst site of relapse for approximately 50%
88 S. Kimbung et al. / Seminars in Cancer Biology 35 (2015) 85–95
Fig. 2. Frequency (%) of site-speciﬁc metastases among 1357 patients with metastatic breast cancer based on molecular subtype. Bone metastases were most prominent
in  the luminal A, luminal B and luminal/HER2 subgroups. Lung metastases were less frequent in the luminal A group compared to all other groups, while high rates of
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ata adapted from [61] with permission from the American Society of Clinical Onco
f breast cancer patients. It is more frequent among patients with
R positive, luminal-type primary breast cancers, whereas patients
ith HER2 positive breast cancers frequently present with metas-
ases in the brain, liver and lung [66]. On the other hand, lung
etastases are commonly diagnosed in patients with ER nega-
ive disease, but other visceral sites, including the brain, are also
ommon among patients with triple-negative (TNBC) or basal-like
reast cancer (Fig. 2) [58,59,61]. Hence, the molecular subtype of
he primary tumor may  to some extent serve as a biomarker for
rediction of future metastatic sites and may  potentially be useful
o direct disease surveillance after adjuvant treatment, although
isease progression to multiple organs is often observed, with
igniﬁcant negative impact on patient survival. An improved under-
tanding of the mechanisms underlying organ-speciﬁc tropism is
herefore required for the development of more effective tools for
rognostication, potentially targeted prevention and treatment of
etastases. Examples of organ-speciﬁc breast cancer metastasis
rogression and virulence genes are discussed below and summa-
ized in Table 1.
.1. Bone metastases
Given that bone is the most common distant metastatic site
or breast cancer and the third most prevalent site of cancer
etastases in general, often associated with severe pain and other
o-morbidities [67], the molecular determinants of bone metas-
ases have been extensively studied and have also been recently
eviewed [68]. Breast cancer cells preferentially cause osteolytic
esions in the bone. TGF- induces osteoclasts to secrete parathy-
oid hormone-related protein (PTHrP), tumor necrosis factor ps. Liver metastases were more frequently seen in the HER2-enriched subgroups.
All rights reserved.
(TNF), and cytokines (including interleukins 1, 6, 8 and 11) which
prompt osteoblasts to release RANKL (the ligand for the recep-
tor activator of nuclear factor-B [RANK]), culminating in the
stimulation of osteoclast differentiation [50,68–70]. Osteoclasts
in turn demineralize bone, thereby releasing growth factors such
as bone morphogenic proteins, IGF1, and TGF from the bone
matrix that support cancer cell proliferation. Other proteins impor-
tant for mediating the specialized functions necessary for cancer
cells to home to and colonize the bone include cytokines (CXCR4,
CXCL12 and TGF), VCAM-1, NF-B, JAGGED1, SRC, SPP1 (also
known as osteopontin, OPN), MMP1  [50,71–75], integrin (avb3)
[76–78], cadherins (e.g. cadherin 11) [79], and adrenomedullin [80].
Recent studies implicate the enzyme lysyl oxidase (LOX), secreted
by breast cancer cells under hypoxia, in inducing bone lesions
speciﬁcally in patients with ER negative breast cancer [81] and
the disruption of heterotypic adherens junctions (hAJs) involving
cancer-derived E-cadherin and osteogenic N-cadherin to abolish
bone metastatic niche-conferred advantages [82]. Furthermore, the
expression of miRNAs miR-141, miR-219 [83] and MiR-34a [84]
were also reported to inhibit bone metastases in a xenograft mouse
model. miR-16 and miR-378 expression were also correlated with
bone metastasis burden and may  serve as potential therapeutic
targets and clinical biomarkers of bone metastases [83].
4.2. Lung metastasesThe development of lung metastases has been linked with
several genes encoding cytokines or secreted products that
support transendothelial migration from circulation into the
lung parenchyma [85–88]. The extracellular matrix components
S. Kimbung et al. / Seminars in Can
Table  1
Examples of organ-speciﬁc breast cancer metastasis progression and virulence
genes.
Organ site Gene GO annotation/function Ref.
Brain
ST6GALNAC5 Protein glycosylation [46]
COX2 (PTGS2) Prostaglandin biosynthesis [46,96]
HBEGF Cell motility [46]
SERPINI (neuroserpin) Serine proteinase inhibitor [97]
L1CAM Cell adhesion [97]
PLG (plasminogen) Proteolysis [97]
Cathepsin S Proteolysis [94]
Liver
CLDN2 Tight junction [51,99,100]
CCL9 Chemokine [98]
CX3CL1 Chemokine [98]
Lung
COX2 (PTGS2) Prostaglandin biosynthesis [47,86]
SPARC Cell adhesion [47,86]
POSTN Extracellular matrix
protein in stem cell niches
[88]
VCAM1 Cell adhesion [47,85]
MMP1  Extracellular matrix
remodeling
[47,86]
MMP2  Extracellular matrix
remodeling
[47,86]
EREG HER/ErbB family ligand [47,86]
ANGPTL4 Vascular regulator induced
by TGF
[87]
MTDH Transcription coactivator
activity
[86]
TNC Extracellular matrix
protein in stem cell niches
[47,88]
ID1 Inhibitor of DNA binding
and transcriptional
activation
[85]
RARRES3 Protein
binding/phospholipase A2
activity
[54]
TGFB1 (TGF) Cytokine [87]
Bone
SDF1 (CXCL12) Chemokine [71,72]
LOX Extracellular matrix
crosslinking enzyme
[81]
IL11 Cytokine [50]
CTGF Connective tissue growth
factor production
[50]
MMP1  Extracellular matrix
remodeling
[73]
ADAMTS1 Disintegrin and
metalloproteinase
[73]
JAG1 (JAGGED1) Notch receptor ligand [74]
SRC Tyrosine protein kinase
activity
[71,72]
NF-B Transcriptional activation
of immune genes
[75]
CXCR4 Chemokine receptor for
SDF1
[69,71,72]
SPP1 (OPN) Integrin-mediated signal
transduction
[50]
PTHLH (PTHrP) Osteoblast development [70]
t
i
c
e
o
c
i
i
b
tVCAM1 Cell adhesion [78]
TGFB1 (TGF) Cytokine [70]
enascin C (TNC) and periostin (POSTN) have been shown to play
mportant roles in the lung metastatic niche of experimental breast
ancer models [88]. TNC is found in stem cell niches and is nec-
ssary for stem cell functions. Through its action on musashi and
ther factors, it enhances NOTCH and WNT  signaling in cancer
ells. Its expression in primary breast tumors was associated with
ncreased risk of lung relapse [47,88]. POSTN was also shown to be
mportant for initiating lung metastatic growth in mouse models
y mechanisms augmenting NOTCH and WNT  signaling [89]. Fur-
hermore, decreased RARRES3 expression was recently associatedcer Biology 35 (2015) 85–95 89
with lung metastatic potential in primary breast cancer [54]. RAR-
RES3 downregulation facilitated the adhesion of the tumor cells to
the lung parenchyma. Thus, TNC overexpression or RARRES3 down-
regulation may  serve as potential biomarkers to identify patients
at high risk of lung relapse. Other noteworthy factors, which
function to mediate lung metastasis, include TGF, epiregulin,
cyclooxygenase-2 (COX-2, gene name PTGS2), matrix metallopro-
teinases (MMP1  and MMP2), angiopoietin-like 4 (ANGPTL4), ID1,
MTDH and VCAM1 [85–88,90,91].
4.3. Brain metastases
HER2 positive breast cancer is associated with a markedly
increased risk of brain metastases compared with other subtypes,
and current effective therapies controlling extra-cranial metastatic
HER2 positive breast cancer has made this even more evident
[92,93]. The severe attrition of metastatic cells in the brain and
the relatively late diagnosis of brain metastases in the clinical dis-
ease course argue that CTCs face major hurdles in colonizing this
organ. The blood–brain barrier (BBB) is composed of endothelial
cells, astrocytes and pericytes which present a daunting structure
for tumor cells to penetrate in order to seed metastases in the
brain. Cathepsin S (CTSS) expression in primary breast tumors was
found to be inversely correlated with brain metastasis-free sur-
vival and its expression in experimental xenografts was shown to
facilitate transmigration of the BBB through cleavage of tight junc-
tion proteins. Inhibition of CTSS prevented the formation of brain
metastases in this model [94]. Kodack et al. recently reviewed the
preclinical and clinical advances in the understanding of the devel-
opment breast cancer brain metastases and possible preventive and
treatment strategies [95]. Evidently, cancer cells utilize specialized
mechanisms to traverse the BBB, and other key molecular media-
tors of this process have been identiﬁed [46,96,97]. Brain metastatic
breast cancer cells express high levels of anti-plasminogen acti-
vator serpins, including neuroserpin (SERPINI1) and serpin B2, to
prevent the generation of plasmin, which suppresses metastasis
formation [97]. COX-2, the epidermal growth factor receptor (EGFR)
ligand HBEGF, the 2,6-sialyltransferase ST6GALNAC5, L1 cell adhe-
sion molecule (L1CAM), neuroserpin and plasminogen (PLG) in
cooperation with astrocytes, pericytes and other cell types in the
brain microenvironment act as mediators of cancer cell passage
through the BBB, collectively contributing to vascular co-option and
survival of breast cancer cells in the brain [46,96,97].
4.4. Liver metastases
Despite being a very common site of breast cancer recurrence,
characterization of the molecular determinants of liver coloniza-
tion is lagging behind. Similar to the bone, brain and lungs,
chemokines secreted by breast cancer cells and their cognate recep-
tors have been associated with breast cancer liver recurrence in
a number of studies. CCL9 and CX3CL1 were strongly and uni-
formly elevated in liver-metastatic breast cancer cells in mice
[98]. CCL9 secreted by cancer cells is important for recruiting
immature myeloid cells which produce MMP2  and MMP9, and
CX3CL1 is required in tumor-associated macrophages to support
angiogenesis which is required for successful colonization of the
liver [98]. The expression of the tight junction protein claudin 2
(CLDN2) was  found to be signiﬁcantly elevated in breast cancer
liver metastases, as well as in primary tumors with an increased
predilection to metastasize to the liver [51,62,99]. Functional evi-
dence characterizing CLDN2 as a breast cancer liver metastasis
progression gene that endows circulating breast cancer cells with
enhanced capability to adhere, survive, and proliferate in the
hepatic microenvironment has been demonstrated [51,99,100].
CXCR4 and its ligand (CXCL12, also known as SDF1), cadherins,
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ntegrins, and other claudins have also been implicated in the devel-
pment of breast cancer liver metastases [51,62,98–101].
Taken together, the common denominator of all these studies is
hat overt colonization of speciﬁc organs critically depends on very
ntricate interactions between disseminated cells and speciﬁc stro-
al  components in metastatic niches. Tumor cell derived proteases
nd their regulators principally undergo stage-speciﬁc changes in
xpression during metastatic seeding and outgrowth in different
rgans, whereas stromal-derived genes are predominantly regu-
ated in a tissue speciﬁc manner.
. Prognostic factors and predictive gene signatures
Although a complete understanding of the etiology of MBC  is
till actively being researched, several factors have been linked
ith an elevated risk of developing MBC. Conventional factors
ssociated with an increased risk of breast cancer recurrence
nd which are widely included in prognostic and treatment
esign decisions in the adjuvant setting include age at the
ime of primary tumor diagnosis [102,103], TNM staging (tumor
ize, nodal status, de novo distant metastatic disease [104–107]),
umor histological grade (Nottingham histological grading sys-
em [108]), ER and progesterone receptor (PR) status [109–113]
nd ampliﬁcation of the human epidermal growth factor recep-
or 2 (HER2) gene [113–116]. Uncontrolled proliferation is one
f the hallmarks of cancer [117,118] and signiﬁcantly inﬂu-
nces the efﬁcacy of cancer chemotherapeutics and radiotherapy.
he expression of the nuclear protein Ki67 has been shown
o correlate with the proliferative rate of tumor cells and this
iomarker has shown independent prognostic utility in primary
reast cancer, especially among patients with ER positive tumors
115,119,120].
The risk of breast cancer recurrence and mortality may  also
ary over time. While patients with ER negative breast cancer
sually develop metastases early (within 5 years), approximately
0% of recurrences in patients with ER positive disease will occur
ollowing a relatively protracted time period (often beyond 5
ears [109]). Also, while the risk of distant recurrence peaks in
he ﬁrst 2–3 years after primary tumor diagnosis and thereafter
eclines among patients with TNBC [121], recurrence risk remains
elatively constant over time among patients with ER positive
reast cancer [122]. Recent advances in genetic proﬁling of tumors
ave extended our understanding of the biology of breast can-
er and more importantly has led to the development of several
rognostic gene signatures (reviewed in [123]) which in combi-
ation with conventional prognostic factors are routinely used
n the clinic for the selection of patients with ER positive breast
ancer who are at the highest risk of early disease recurrence
within 5 years), and who may  beneﬁt from extended endocrine
reatment.
Several phase III trials have been also been conducted to
rospectively evaluate the effect of extended endocrine treat-
ent with tamoxifen (ATLAS [124]) or aromatase inhibitors (MA.17
125], NSABP-B33 [126] and ABCSG [127]) beyond 5 years for ER
ositive breast cancer, and it is becoming more apparent that
xtended endocrine therapy can reduce the risk of late recurr-
nces in the decade after completing 10 years of endocrine
reatment, i.e. in the second decade after initial breast cancer diag-
osis [124,126,127]. Unfortunately, identifying patients who  are at
ncreased risk of developing a late recurrence remains a challenge.
ikewise, sparing patients at low risk from unnecessary treat-
ents, that may  also be associated with serious adverse effects,
emains an unmet clinical need. A few retrospective studies have
alidated the applicability of multi-gene signatures for predict-
ng late recurrence risk in ER positive breast cancer. The PAM50cer Biology 35 (2015) 85–95
risk-of-recurrence (ROR) score (a Nanostring® assay, which based
on PAM50 intrinsic subtypes, tumor size and proliferation, and
incorporating the number of positive lymph nodes, categorizes
patients into a low, intermediate or high risk group) was shown
to differentiate patients with respect to risk for late recurrence
beyond conventional prognostic factors [128,129]. EndoPredict, a
qRT-PCR-based score combining the expression levels of eight pro-
liferative and ER signaling genes, stratiﬁed patients at risk after
5 years of endocrine treatment into a low risk group with an
absolute risk of 1.8% of developing late distant metastases at 10
years of follow-up. Inclusion of the clinical risk factors tumor size
and nodal status improved the prediction of late recurrences fur-
ther [130]. In addition, the Breast Cancer Index (BCI, a qRT-PCR
assay based on the ﬁve-gene molecular grade index (MGI) and the
HOXB13/IL17B ratio) [131] and the 70-gene microarray prognosis
signature MammaPrint® [132] also provided additional progno-
stic information for the identiﬁcation of late distant recurrences in
selected subgroups. These predictors may  be helpful in identifying
patients for extended therapy after ﬁve years of initial endocrine
treatment. However, larger prospective randomized trials investi-
gating the extent to which these signatures predict the beneﬁt of
extended endocrine treatment need to be conducted.
To address the impact of receiving adjuvant chemotherapy for
breast cancer on survival following distant recurrence, a large
meta-analysis was  recently performed by Tevaarwerk and col-
leagues [133]. This meta-analysis of post distant disease recurrence
survival included 13,785 breast cancer patients who  had received
adjuvant chemotherapy within 11 trials coordinated by the East-
ern Cooperative Oncology Group (ECOG) over a period of 30 years.
A marginal improvement in survival over the past 30 years was
noted for the entire population, but this effect was not maintained
when the analysis was adjusted for distant recurrence-free inter-
val (DRFI) and hormone receptor status. In fact, survival improved
over time only in those patients with hormone receptor negative
disease with a DRFI ≤ 3 years, which may  be largely attributed to
the introduction of targeted therapy for patients with HER2 posi-
tive tumors. In general, the availability of new therapeutic agents
has not broadly translated into improved survival for many women
who develop distant recurrences after adjuvant chemotherapy.
There hence remains a critical need for the development of more
effective therapies for patients with MBC.
6. Predicting site/s of metastasis
Predicting the future metastatic site/s of a primary breast
cancer is multifaceted and challenging. As previously pointed
out, molecular subtypes of breast cancer may  provide marginal
metastasis site-speciﬁc prognostic information, but more accu-
rate site-speciﬁc biomarkers are needed. Multigene signatures
that may  be useful in predicting breast cancer relapse to the
bone, lung and brain in clinical tumor cohorts have been pub-
lished [46,47,50,71,87,134], but further studies to validate the
site-speciﬁc predictive potential of these signatures are required.
As mentioned previously, several metastasis progression genes
have also shown potential as independent site-speciﬁc prognostic
biomarkers. A recent study by Wolf and colleagues aiming to ﬁnd
gene expression modules active in breast cancer subpopulations
identiﬁed three independent gene modules enriched for extracellu-
lar matrix (i.e. stroma) genes which showed signiﬁcant associations
with the site of recurrence [135]. Furthermore, we  have recently
shown that claudin-2 expression in primary tumors is predictive
of liver-speciﬁc recurrence [62]. Prospective studies are warranted
to validate the analytical validity and clinical utility of these
biomarkers.
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. Longitudinal heterogeneity of conventional prognostic
nd treatment predictive markers during disease
rogression
Following the plethora of changes tumor cells must undergo to
eed clinically detectable metastases, the level of intra- and inter-
umoral heterogeneity between primary tumors and metastases
bserved at the molecular level is not surprising. Remarkable het-
rogeneity in the mutational spectrum, copy number alterations,
ranscriptomes and epigenomes between primary tumors, CTCs,
TCs and metastases has been revealed through high-throughput
olecular proﬁling studies. More recently, studies exploring this
nter-tumor heterogeneity proposed a novel classiﬁcation of breast
ancer that integrates genomic and transcriptomic information to
lassify primary tumors into 10 subtypes with distinct clinical out-
omes [136,137]. Furthermore, the heterogeneity within individual
ubtypes, e.g. the TNBC subtype, can also be deconstructed to iden-
ify stable sub-groups with distinct molecular, pathological and
linical features [138].
There is a growing recognition that intra-tumor heterogene-
ty within the same patient is clinically relevant and the status
f treatment predictive biomarkers may  also evolve during tumor
rogression. Discordant expression of ER, PR and HER2 between
rimary breast tumors and their matched metastatic lesions has
een extensively reported (recently reviewed in [31]). Further-
ore, a meta-analysis showed that the rates of discordance for ER,
R and HER2 status were 20%, 33% and 8%, respectively [139] with
he conversion to negative receptor status at recurrence, on aver-
ge, higher than the positive conversion (24% vs. 14% for ER, 46%
s.15% for PR, and 13% vs. 5% for HER2) [139]. In a recently conducted
rospective analysis, conversion rates determined at local laborato-
ies were found to be higher than those determined centrally (21%
s. 13% for ER, 35% vs. 28% for PR and 16% vs. 3% for HER2, respec-
ively) [140]. Fewer studies have however reported on the effects
f biomarker discordance on decisions regarding treatment choice
nd overall survival. In a pooled analysis of the prospective BRITS
nd DESTINY studies [33], biopsy results altered management in
4.2% of cases, with rates ranging between 17-31% within prospec-
ive clinical trials [140–143]. Of note, modiﬁcation of therapy was
ore common when there was gain of receptor expression, while
ther retrospective studies have associated loss of ER expression
ith an inferior post-recurrence survival [34–37] but this has not
een prospectively investigated.
Tumor heterogeneity of breast cancer therefore represents
 severe impediment to the successful clinical management of
reast cancer. The signiﬁcant molecular/genetic differences within
ndividual cancers, between primary cancers and their paired
etastases and potentially between metastases within the same
atient, have serious implications for treating metastatic disease.
herapeutic management of MBC  still largely depends on historical
ata for treatment predictive biomarkers assessed in the primary
umor. This paradigm is now gradually changing and biopsies of
etastases are routinely collected whenever possible for reassess-
ent of biomarkers, in compliance with clinical guidelines [1,144].
he decision regarding when and how to re-assess biomarkers and
hich metastasis to sample is however not an easy one, since many
atients are often diagnosed with multiple metastases. Obtain-
ng a metastasis biopsy is an invasive and costly measure and is
omewhat restricted in that it may  only provide a snapshot of
he tumor molecular proﬁle at a given time or organ site, but has
ecome clinical routine in patients with a clinical or radiological
uspicion of metastatic disease. There is clear evidence suppor-
ing the prognostic value of analyzing biomarkers in a metastatic
iopsy, but to our knowledge any formal proof of an ameliorated
utcome if treatment is directed based on information from the
etastasis is not yet available. This does of course not exclude thecer Biology 35 (2015) 85–95 91
possibility that such beneﬁt may  in fact exist. Intuitively, it is illog-
ical to treat a manifest ER-negative breast cancer lesion from a
surgically removed ER-positive primary tumor with an endocrine
agent. Furthermore, biopsies of suspected breast cancer metastases
regularly identify an unrelated malignant or even benign disease
[34], with obvious fundamental implications for the treatment of
the individual patient. Taken together, obtaining a biopsy at time
of ﬁrst metastasis diagnosis is highly recommended for diagnosis
veriﬁcation, to guide treatment and for research purposes. Re-
assessment of resistant clones may  be considered thereafter [31].
A possible strategy to reduce the risks associated with repeated
biopsies may  be to use non-invasive liquid biopsies instead. Anal-
ysis of CTCs can be used to predict/monitor treatment response
for personalizing treatments [38,39] and emerging data indicate
that genomic alterations in solid cancers can be reliably charac-
terized through massively parallel sequencing of circulating ctDNA
released from cancer cells into plasma [40,145,146]. These meth-
ods are however also technically challenging and expensive and do
not fully capture the molecular heterogeneity of metastases. Fur-
ther translational research is clearly warranted in this important
ﬁeld.
8. Treatment in early and metastatic breast cancer
The main goal in the treatment of breast cancer is to pro-
long survival and to maintain or improve quality of life for the
patient. To achieve this, a large palette of anti-neoplastic medi-
cal treatments is at hand for use in the adjuvant – i.e. treatment of
presumed micro-metastatic disease – and metastatic setting – i.e.
treatment of macro-metastatic disease [1,144,147,148]. Conven-
tional chemotherapy aims to eradicate proliferating cells, whereas
targeted treatments including endocrine manipulations and HER2-
directed treatments are mainstay in ER positive [149,150] and
HER2 positive disease respectively [151], affecting central signaling
mechanisms in tumors expressing these speciﬁc targets. An
increasing number of other pathway directed drugs including
mTOR inhibitors [152,153], PI3 kinase inhibitors [154,155] and
cyclin dependent kinase inhibitors [156] have been or are currently
being developed, often in combination with endocrine treatments
or chemotherapy. Anti-angiogenic drugs [157,158] and drugs inter-
acting with bone metabolism are being used, as well as PARP
inhibitors that seem to have a speciﬁc role in the treatment of BRCA
deﬁcient tumors with decreased DNA repair capabilities [159–161].
With the exception of the bone directed treatments with bis-
phosphonates in postmenopausal women with early breast cancer
[162,163] and the RANK ligand antibody denosumab [164], none
of these medical treatments speciﬁcally aim at the treatment of a
speciﬁc metastatic site. Instead, they typically exert their actions
more generally toward features distinguishing tumor cells from
normal cells, in most cases proliferation. In some instances, com-
panion diagnostics indicating potential responsiveness to the drug
at hand are available; in most cases however, such biomarkers are
unfortunately lacking.
9. Clinical translation
The development of successful strategies to treat and possibly
prevent metastases will depend on even deeper understanding of
the complexity of the multi-step processes of metastasis devel-
opment, including the interplay between cancer cells and the
local/distant microenvironment. Given the evidence supporting the
parallel progression model, in which dissemination occurs in the
early stages of disease progression, developing targets for the initial
steps of metastasis is challenging. Also, while mutational and trans-
criptional landscapes of primary tumors and metastases may  be
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airly similar overall, anti-metastatic treatment may  need to target
undamentally different mechanisms than standard chemothera-
eutics, which are generally anti-proliferative and therefore most
fﬁciently eliminate rapidly growing cells. The extensive latency
eriod often observed in e.g. ER positive breast cancer patients
mplies that the DTCs present during this time are dormant and
ot primed to establish secondary tumors in the absence of certain
olecular or environmental cues. Dormant cells also generally have
ow metabolic and proliferative activity, rendering them insensi-
ive to conventional anti-cancer drugs. Understanding the signals
hat affect DTC turnover, and the properties required for these cells
o maintain a viable state despite latency, should provide valuable
lues for therapeutic intervention against minimal residual disease,
nd in addition, metastasis progression and virulence genes may
onstitute the most viable targets for efﬁcient anti-metastasis treat-
ent. In addition, as metastatic relapse is often associated with
esistance to therapy, especially in the case of targeted therapies,
his will require extensive molecular and functional understanding
f resistance mechanisms that likely are unique to each drug/target.
ronically, targeted adjuvant therapy may, while controlling sys-
emic disease, favor metastatic colonization of speciﬁc organs;
.g. the increased incidence of brain metastases in patients with
ER2 positive breast cancers treated with the monoclonal antibody
rastuzumab [92,93].
Our knowledge of mediators of organ tropism in breast cancer
etastasis has increased tremendously in the past decades, and the
dentiﬁcation of tissue speciﬁc prognostic signatures might provide
ore tailored treatment options. Nevertheless, while these studies
rovide mechanistic insight into organ speciﬁc metastasis, the vast
ajority are based on genetically or molecularly engineered ani-
al  models. Improved models, reﬂecting the natural (spontaneous)
ourse of metastasis development as well as the selective pressure
aused by (adjuvant) treatment will be required for the realization
f viable anti-metastatic treatment modalities. Therapies that tar-
et the mechanisms that render dormant micrometastases active
ill also be required. Efﬁcacious cancer treatment will need to com-
ine multiple anti-metastatic drugs with cytotoxic chemotherapy
n the adjuvant setting. If micrometastases, whether dormant or
ctive, are on the move between dormant niches and sites of metas-
asis, combination treatments will be required to prevent further
eseeding and growth at metastatic sites. Interaction with host
actors may  also play a role. Examples include associations with
nherited factors leading to tumors of a speciﬁc subtype (e.g. lob-
lar breast cancer in carriers of inherited mutations in the gene
ncoding E-cadherin (CDH1)), or general DNA repair deﬁciency (e.g.
he BRCA genes), subtypes with speciﬁc metastatic propensities.
ore recently, is has been shown in a recent meta-analysis that
djuvant treatment with bisphosphonates seems to preferentially
eneﬁt postmenopausal women with breast cancer rather than
remenopausal [163], highlighting the effect of host mechanisms.
Given the molecular and clinical complexity of breast cancer
etastases outlined herein, it is clear that the design of effec-
ive drugs, therapeutic approaches, and clinical trials involving
nti-metastatic agents face a number of challenges. So, what are
he conceptual shifts that will be needed for this development?
hich changes can we envision? Liquid (in early and advanced
tage disease) or metastatic (in advanced stage disease) biopsies
ill likely become mandatory in clinical work-up. The proﬁle of a
atient’s primary/metastatic tumor or liquid biopsy could include
ot only histopathological or genetic determinants of prognosis
r treatment prediction, but also a molecular snapshot indicat-
ng metastatic propensity, a measure of how adept the cells are
ith respect to metastatic functions, adding crucial information to
 prognostic framework. If preventative measures are to succeed in
he clinic, methods to identify predisposed patients are necessary,
nd this will entail identiﬁcation of the expression of biomarkers incer Biology 35 (2015) 85–95
primary tumors and/or systemic metastases. Further, cancer ther-
apy might be dictated by the metastatic site/s, and not only by the
speciﬁc tissue (and subtype) of origin. A current example of a site
speciﬁc metastasis targeting treatment is the use of bisphospho-
nates or denosumab (an anti-RANK antibody), or both, to treat bone
metastases originating from e.g. breast cancer. Drug regimens for
patients with cancer might include multiple drugs targeting differ-
ent metastatic sites and seeding among sites. Taken together, the
emerging ability to identify tissue tropic biomarkers and the matur-
ing of the ﬁeld of predictors of prognosis hold promise to eventually
allow oncologists to direct treatment plans to those patients and
tissues most at risk. There is now hope for achieving the ultimate
goal in cancer treatment - curing metastatic disease.
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